FOXO4-DRI alternatives.

7 compounds compared to FOXO4-DRI, ranked by published evidence tier and regulatory status, not by what's marketed hardest.

Why people look for an alternative

FOXO4-DRI is a proof-of-concept object, and people usually search for alternatives once they see that clearly. It is a D-retro-inverso peptide built from D-amino acids in reversed sequence to mimic FOXO4's p53-interacting surface while resisting protease breakdown, and it was reported in 2017 as a tool for selectively eliminating senescent cells. It is investigational and research-use-only, not approved by any major regulator, not a marketed drug, and it has no DailyMed monograph. There is no approved senolytic to move to, in peptide form or otherwise, so the compounds listed below share the longevity category with it rather than offering a better-supported route to the same effect.

What you're comparing against
FOXO4-DRI
F tier · 15/100Research / preclinical

FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4).

Ranked by evidence · strongest first
  1. 01
    Epitalon
    F tierResearch / preclinical

    Acts through the senescence and cellular ageing pathways pathway, like FOXO4-DRI. Research / preclinical.

  2. 02
    5-Amino-1MQ
    F tierResearch / preclinical

    Acts through the senescence and cellular ageing pathways pathway, like FOXO4-DRI. Research / preclinical.

  3. 03
    SS-31
    C tierIn human trials
    elamipretide

    Same category: longevity. In human trials.

  4. 04
    Glutathione
    D tierResearch / preclinical
    GSH · reduced glutathione

    Same category: longevity. Research / preclinical.

  5. 05
    MOTS-c
    F tierResearch / preclinical

    Same category: longevity. Research / preclinical.

  6. 06
    Humanin
    F tierResearch / preclinical

    Same category: longevity. Research / preclinical.

  7. 07
    Vilon
    F tierResearch / preclinical
    Lys-Glu dipeptide

    Same category: longevity. Research / preclinical.

How this list is built

An “alternative” here means a compound that shares FOXO4-DRI's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.

Comparing options with your provider?

PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page
Compounds